


Women in Life Science Denmark (WiLD) launches its Female Leadership Mentoring Program to support career advancement for women in life science
WiLD is a professional network of executive women aiming to leverage…

Ariceum Therapeutics’ targeted radiopharmaceutical 177Lu-satoreotide exhibits promising clinical response and good tolerability profile in patients with advanced neuroendocrine tumours
95% of patients (36 of 38) treated with Ariceum’s radiopharmaceutical…

4SC receives Orphan Drug Designation (ODD) for resminostat (Kinselby) in CTCL from the US FDA
The US Food and Drug Administration (FDA) has granted 4SC’s…

Acesion Pharma Closes Oversubscribed €45M Series B Financing Round
Financing co-led by new investors Canaan and Alpha Wave, and…

4SC: Landmark RESMAIN study data presented at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting
Maintenance therapy is now clinically proven to postpone disease…

Novo Holdings advances antimicrobial resistance strategy with acquisition of Paratek Pharmaceuticals
Paratek’s successful commercialisation platform to advance…

Leucid Bio Granted MHRA Clinical Trial Authorisation for Lateral NKG2D CAR T-Cell Therapy LEU011
Company on-track to dose first patient in LEU011 Phase 1/2…

New cell therapy facility enters fight against chronic diseases
The Novo Nordisk Foundation has committed up to DKK 950 million…

Poolbeg Pharma plc – Immunomodulator I Patent Portfolio Strengthened
20 September 2023 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF,…

Novo Holdings invests in innovative water treatment pioneer, HPNow, as part of €14m round
Copenhagen, Denmark – Novo Holdings A/S, a leading global…

Futura Medical plc – Interim Results 2023
Futura Medical plc (AIM: FUM), the pharmaceutical company developing…

4SC: RESMAIN study data to be presented at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting
Planegg-Martinsried, Germany, 15 September 2023 – 4SC AG…

Glentra Capital, a new energy transition investment firm backed by large Danish investors, announces first close of EUR 443 million
COPENHAGEN, DENMARK – September 14, 2023. With a total commitment…

HERVOLUTION Therapeutics appoints Moderna Co-Founder and MIT Professor Robert S. Langer as Chair of its Scientific Advisory Board
Prof Langer is a world-renowned scientist and entrepreneur who…

ABL Bio Taps into Synaffix ADC Technology
License from Synaffix focuses on bispecific ADCs
This…

Poolbeg Pharma plc – Interim results for the six months to 30 June 2023
Significant progress made and well positioned for future growth
13…

IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer
Encouraging interim data support the potential of IO102-IO103…

Ariceum Therapeutics doses first patient with its first-in-class targeted radiopharmaceutical drug satoreotide in its Phase Ib study in small cell lung cancer
Ariceum develops satoreotide its first and best-in-class somatostatin…

IO Biotech Announces Participation in Upcoming Investor Conferences
NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq:…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York